Full Press Release featured on Enterome Bioscience.
Enterome Bioscience and the Center for Individualized Medicine at Mayo Clinic have entered into an agreement to begin collaboration focused on the discovery and validation of gut microbiome based diagnostic tests for predicting responses to medical nutritional intervention in overweight or obese patients.
"It is well known that a healthy diet and regular exercise are key to losing weight, but there is another factor that may be just as influential - a person's microbiome," said Vandana Nehra, M.D., Division of Gastroenterology and Hepatology, Mayo Clinic. "This study will use a weight loss program at Mayo Clinic to examine the effect of intervention with diet and exercise on the microbiome."
A panel of bacterial biomarkers from the gut microbiome, known collectively as MET 230, were identified by Enterome's scientific founder Dusko Ehrlich and collaborators at the French National Institute for Agricultural Research (INRA) and the Institute of Cardiometabolism and Nutrition (ICAN). These biomarkers enable the stratification of patients based on the health and diversity of their personal gut microbiome, and with a recent 400-patient study, they have been correlated to the metabolic profile of obese patients as well as to their responsiveness to nutritional intervention.
"The signing of this agreement with Mayo Clinic is another key corporate milestone for Enterome, and I am very pleased Mayo Clinic will work with us on such an important project. It is clear that new personalized medicine/nutrition solutions are needed if we are going to properly address the growing problem of obesity and its negative impact on public health," said Pierre Belichard, CEO of Enterome.
Mayo Clinic is conducting a study currently to characterize the gut microbiome before and after dietary intervention. This study, if successful, would enable the commercialization of a personalized nutrition test for patients with obesity associated with low grade inflammation and certain metabolic risk factors.
One-third of the US population is currently obese, and this proportion is expected to increase to 50% by 2030. Nearly $200 billion annually is spent on obesity-related illnesses in the US; while approximately 40% of the US population is dieting at any point in time, resulting in a market for weight management products worth $20 billion per year.
From this scientific finding, Enterome, under a license agreement with INRA, is developing a diagnostic test dedicated to the management of obesity and personalization of medical nutrition to patient's needs. It is hoped that the application of Enterome's technology will be a key driver for improving the outcome of stratified nutritional strategies and in the future the development of novel drugs or functional food products aiming to decrease comorbidities associated to overweight and obesity (i.e. type 2 diabetes).